KRYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Krystal Biotech Inc (KRYS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong financial growth, positive analyst ratings with consistent price target increases, and a promising pipeline of products. While there are no immediate trading signals or significant news catalysts, the technical indicators and options data suggest a stable entry point for long-term growth.
The technical indicators are moderately bullish. The MACD is positive and contracting, suggesting upward momentum. The RSI is neutral at 48.032, indicating no overbought or oversold conditions. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200. The current price is near the pivot level of 268.035, with key resistance at 276.917 and support at 259.154.
Strong financial performance in Q4 2025 with revenue up 17.52% YoY and net income up 13.02% YoY.
Positive analyst sentiment with multiple price target increases, including Citi and Jefferies raising targets to $
Promising pipeline with Vyjuvek showing strong growth and upcoming catalysts in ophthalmology and cystic fibrosis.
No significant news or event-driven catalysts in the recent week.
Gross margin slightly declined by -0.76% YoY, though still high at 93.85%.
In Q4 2025, Krystal Biotech reported strong financial growth: Revenue increased by 17.52% YoY to $107.1M, net income rose by 13.02% YoY to $51.4M, and EPS grew by 11.84% YoY to 1.7. Gross margin remains high at 93.85%, though it slightly declined by -0.76% YoY.
Analyst sentiment is highly positive. Multiple firms, including Citi, Jefferies, and Goldman Sachs, have raised their price targets significantly, with the highest target at $371. Analysts highlight strong Vyjuvek sales, a robust pipeline, and potential growth in ophthalmology and cystic fibrosis markets.
